Spring Selection 2018

read more

currently open
closes 7 Jan 2018

Research Groups

Portrait Ali El-Armouche

Ali El-Armouche

Novel therapeutic approaches for the prevention of lethal arrhythmias and heart failure progression

Previous and Current Research

The main focus of my group is to identify molecular mechanisms in arrhythmogenesis and heart failure progression with emphasis on novel nodal points in cardiac signaling. We aim to enhance the understanding of cardiac molecular signaling and to identify and promote new candidate targets for pharmacologic interventions. Our strategy is to use screening techniques to uncover new players followed by validation in gene targeted mice (conventional and conditional transgenesis) in order to test novel treatment strategies in a joint translational research activity.

We are presently working on testing the therapeutic potential of protein phosphatase modulation (see figure, e. g. the PP1 inhibitor I-1) in arrhythmogenesis. By screening of human and experimentally failing hearts we identified I-1 to be markedly deactivated. Genetic ablation of I-1 protected the heart against lethal arrhythmias. In contrast, conditional overexpression (Tet-Off-system) of I-1 increased contractile performance, but also the propensity towards lethal arrhythmias. We therefore propose that pharmacological inhibition of I-1 may represent an attractive new therapeutic strategy.

As for I-1, we have initiated similar approaches for cyclic nucleotide phosphodiesterase (PDE) isoforms. Among the PDE superfamily, the PDE2 isoform is unique in being activated by cGMP. PDE2 is upregulated in human as well as in experimental heart failure but its physiological and pathological role in the heart remained unknown. We showed for the first that the physiological role of PDE2 is predominantly confined to heart rate regulation. Specific inhibition of PDE2 in dogs and mice led to an exclusive increase in heart rate, while heart-specific overexpression resulted in its decrease. Under chronic pathological conditions, PDE2 protected the heart from excessive sympathetic stress. Moreover, under acute stress, higher PDE2 abundance effectively protected against ventricular arrhythmia by reducing intracellular calcium leakage. Therefore we will start a gene-therapeutic approach by testing the benefit of AAV9-mediated PDE2 overexpression test how these interventions are compared to conventional beta-blockade (e.g. metoprolol as a mainstay in human heart failure therapy) in the setting of preexisting experimental heart failure in mice.

Ali El-Armouche Research: figure
Role of phosphatases in arrhythmogenesis. Altered protein-phosphatase activity in AF and HF can promote reentry by reducing ICa,L and increasing inward-rectifier K+-currents, shortening the effective refractory period (Mechanism 1), and via dephosphorylation of INa and connexins, reducing intracellular communication (Mechanism 2). Increased inhibitor-1 (I-1) in AF results in a local PP1 reduction and increased RyR2 and PLB phosphorylation, increasing the likelihood of ectopic-activity-promoting spontaneous SR Ca2 +-release events (Mechanism 3). Increased calcineurin-mediated NFAT dephosphorylation and subsequent nuclear translocation activate profibrotic and prohypertrophic gene transcription pathways (Mechanism 4), Heijman J et al. 2013 J Mol Cell Cardiol 64:90-8.
Future Projects and Goals

Heart failure has a higher prevalence and worse prognosis than most cancers. Stopping or reverting heart failure progression is a global challenge that requires new therapeutic paradigms. Our ultimate goal is to advance heart failure therapy and to prevent sudden cardiac death. To archive this aim we will elucidate on the mechanistical level and target for pharmacological intervention:

  1. Molecular mechanisms of heart failure and arrhythmogenesis with focus on signal transduction
  2. Cross talk mechanisms of myocardial phosphatases, phosphodiesterases and kinases
  3. Myocardial plasticity: hypertrophy, atrophy und remodeling
  4. Regulatory epigenetic mechanisms and histone modifying enzymes in the heart
  5. Redox-mediated signaling mechanisms in cardiac cells
Methodological and Technical Expertise
  1. Experimental heart failure and lifestyle mouse models
  2. Echocardiography in small animals
  3. ECG telemetry and electrophysiology
  4. Mouse genetics: Cre-LoxP system, knock-in technology, conditional technologies
  5. Small molecule high throughput screening
  6. Translation towards DNA-based therapies via AAV technology
Selected Publications

Mehel H, Emons J, Vettel C, Wittköpper K, Seppelt D, Dewenter M, Lutz S, Sossalla S, Maier LS, Lechêne P, Leroy J, Lefebvre F, Varin A, Eschenhagen T, Nattel S, Dobrev D, Zimmermann WH, Nikolaev VO, Vandecasteele G, Fischmeister R, El-Armouche A
Phosphodiesterase-2 is upregulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes.
J Am Coll Cardiol.; 62:1596–606. IF 15.3 (2013)

El-Armouche A, Wittköpper K, Fuller W, Howie J, Shattock MJ, Pavlovic D
Phospholemman-dependent regulation of the cardiac Na/K-ATPase activity is modulated by inhibitor-1 sensitive type-1 phosphatase.
FASEB J., 25:4467–75. IF 5.5 (2011)

Wittköpper K, Fabritz L, Neef S, Ort K, Grefe C, Unsöld B, Kirchhoff P, Maier LS, Hasenfuß G, Dobrev D, Eschenhagen T, El-Armouche A
Constitutively active inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging.
J Clin Invest., 120:617–26. IF 13.8 (2010)

El-Armouche A, Boknik P, Eschenhagen T, Carrier L, Knaut M, Ravens U, Dobrev D
Molecular determinants of altered Ca2+-handling in human chronic atrial fibrillation.
Circulation, 114:670–80. IF 14.9 (2006)

El-Armouche A, Rau T, Zolk O, Ditz D, Pamminger T, Zimmermann W-H, Jäckel E, Harding SE, Boknik P, Neumann J, Eschenhagen T
Evidence for phosphatase inhibitor-1 playing an amplifier role in β-adrenergic signaling.FASEB J., 17:437–39. IF 5.5 (2003)

CV

since 2014
W3-Professor and Director, Institute for Pharmacology & Toxicology, University of Technology Dresden

2009–2014
W2-Professor and Vice-Director, Department of Pharmacology, University Medical Center Göttingen

2002–2009
Group leader and Principal Investigator, Institute for Pharmacology & Toxicology, University of Hamburg

1999–2002
“Arzt im Praktikum” and research associate, Department of Cardiac Surgery (Chair: Prof. S. Hagl) University Hospital Heidelberg, and Institute for Pharmacology & Toxicology (Chair: Prof. T. Eschenhagen), University Erlangen

1992–1999
University of Freiburg and University of Hamburg, Medicine, MD

Contact

Institut für Pharmakologie und Toxikologie
Technische Universität Dresden
Faculty of Medicine Carl Gustav Carus
Fetscherstraße 74
01307 Dresden

Homepage

Intranet